Story of The Black and White Devils- Mucormycosis and Aspergillosis: A Distinct Entity with Rising Clinical Presentation in COVID Era
Journal of Otorhinolaryngology and Facial Plastic Surgery,
Vol. 10 No. 1 (2024),
13 March 2024
,
Page 1-6
https://doi.org/10.22037/orlfps.v10i1.47249
Abstract
Background: Background: Fungal rhino-sinusitis is a rare, rapidly progressing, life-threatening opportunistic infection, primarily affecting immunocompromised patients, such as those with diabetes and lung diseases, recently observed in post-COVID pneumonia cases. Clinically, it presents with partial neurological dysfunction and progressive necrosis secondary to blood vessel invasion and thrombosis, potentially involving the cranium, increasing morbidity and mortality. First-line treatment includes antifungal therapy, followed by surgical intervention.
Aim: To emphasize the significance of timely diagnosis and treatment strategies for Rhino-orbital-cerebral Mucormycosis and Aspergillosis.
Methods: Since the coronavirus outbreak in India, our hospital has treated thousands of patients, including nine confirmed cases of invasive fungal rhino-sinusitis from April to July 2021. We collected data from electronic records to ensure accuracy, with diagnoses based on clinical presentation, nasal endoscopy, imaging, KOH mount, fungal culture, and histopathology. Our team provided tailored medical and surgical management to meet each patient’s needs, demonstrating our commitment to high-quality care during this challenging time.
Results: Five out of nine patients survived our treatment; the mortality rate was reported as 37.5%, with one patient lost to follow-up.
Conclusion: Timely surgical intervention, effective debridement, and appropriate antifungal therapy can significantly reduce mortality and morbidity in patients with Rhino-orbital-cerebral Mucormycosis and Aspergillosis.
- Mucormycosis; Aspergillosis; COVID19; Amphotericin B; Rhizopus; Case series.
How to Cite
References
Zhou F, Yu T, DuR, et al.: Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020,395:1054-62. 10.1016/S0140-6736(20)30566-3
MishraN,Mutya VSS, Thomas A, RaiG, ReddyB, MohananAA, et al. A case series of invasive mucormycosis in patients with COVID-19 infection. Int J Otorhinolaryngol Head Neck Surg 2021;7:867-70.
Scott brown’s otorhinolaryngology head and neck surgery; vol1; ch96; page 1047-1057
Zeinab Mehrabi, Maryam Salimi, Kianoush Niknam, Farzaneh Mohammadi, Hesan Jelodari Mamaghani, Mohammad Reza Sasani, Mohammad Javad Ashraf, Amir hossein Salimi, Mohammad Hassan Zahed roozegar, Zohreh Erfani, "Sino orbital Mucormycosis Associated with Corticosteroid Therapy in COVID-19 Infection", Case Reports in Ophthalmological Medicine, vol. 2021, ArticleID9745701, 7 pages, 2021.
Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia. 2020;185: 599-26.
Singh Y, Ganesh V, Kumar S, et al. (July03,2021) Coronavirus Disease-Associated Mucormycosis from a Tertiary Care Hospital in India: A Case Series. Cureus 13(7):e16152. doi:10.7759/cureus.16152 Balai E, Mummadi S, Jolly K, et al. (November 29, 2020) Rhino cerebral Mucormycosis: A Ten-Year Single Centre Case Series. Cureus12(11):e11776. doi:10.7759/cureus.11776
Patel D J, Patel P G, Patel P P, Sapariya B, Parmar M B, Diwanji N S. Case series of mucormycosis occurring in patients of COVID-19. IntJ Res Med Sci 2021;9:1746-50.
Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009; 48(12):1743-1751. doi: 10.1086/599
Balai E, Mummadi S, Jolly K, et al. (November 29, 2020) RhinocerebralMucormycosis: A Ten-Year Single Centre Case Series.Cureus12(11):e11776. doi:10.7759/cureus.11776
Roden M M, Zaoutis T E, Buchanan W L, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005, 41:634-53.10.1086/432579
Onyango J F, Kayima J K, Owen WO: Rhino cerebral mucormycosis: case report. EastAfrMedJ.2002,79:390-393.10.4314/eamj.v79i7.8845
Petrikkos G, Skiada A, Lortholary O, et al.: Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012,54:23-34.10.1093/cid/cir866
Nezafati S, Kazemi A, Asgari K,et al.: Rhino cerebral mucormycosis, risk factors and the type of oral manifestations in patients referred to a University Hospital in Tabriz, Iran 2007-2017. Mycoses. 2018,61:764-769.10.1111/myc.12802
Kolekar JS: Rhino cerebral mucormycosis: a retrospective study. IndianJOtolaryngolHeadNeckSurg.2015,67:93-96.10.1007/s12070-014-0804-5
Singh AK, Singh R, Joshi SR, MisraA. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and inIndia. DiabetesMetabSyndr.2021; 15(4):102146.doi:10.1016/j.dsx.2021.05.019
Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post corona virus disease mucormycosis: a deadly addition to the pandemic spectrum. J LaryngolOtol. 2021; 1-6.
Sachdeva K. Rhino-oculo Cerebral Mucormycosis with Multiple Cranial Nerve Palsy in Diabetic Patient: Review of SixCases. Indian J Otolaryngol Head Neck Surg.2013; 65(4):375-379.doi:10.1007/s12070-013-0659-1
- Abstract Viewed: 102 times
- PDF Downloaded: 62 times